Department of Hematology/Oncology,
Tisch Cancer Institute,
Department of Hematology/Oncology, Tisch Cancer Institute
Matthew Galsky has not added Biography.
If you are Matthew Galsky and would like to personalize this page please email our Author Liaison for assistance.
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar, 2005 | Pubmed ID: 15735119
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug, 2005 | Pubmed ID: 15939919
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2005 | Pubmed ID: 16033836
The role of taxanes in the management of bladder cancer.
The oncologist Nov-Dec, 2005 | Pubmed ID: 16314289
A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Cancer Jan, 2006 | Pubmed ID: 16329138
Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.
Urology Feb, 2006 | Pubmed ID: 16461102
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
Cancer Aug, 2006 | Pubmed ID: 16773629
Problems with the randomized discontinuation design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Oct, 2006 | Pubmed ID: 17008711
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
Investigational new drugs Jun, 2007 | Pubmed ID: 17146733
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Cancer Feb, 2007 | Pubmed ID: 17200962
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Clinical genitourinary cancer Dec, 2006 | Pubmed ID: 17239282
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
Nature clinical practice. Urology Mar, 2007 | Pubmed ID: 17297500
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Urology Feb, 2007 | Pubmed ID: 17320659
Outcomes and prognosis in advanced renal cell carcinoma.
Expert review of anticancer therapy Jun, 2007 | Pubmed ID: 17555394
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
Cancer Dec, 2007 | Pubmed ID: 17941029
Germ-cell tumors.
The New England journal of medicine Oct, 2007 | Pubmed ID: 17969229
Novel agents for muscle-invasive and advanced urothelial cancer.
BJU international Apr, 2008 | Pubmed ID: 18005203
Current optimal chemotherapy for advanced urothelial cancer.
Expert review of anticancer therapy Jan, 2008 | Pubmed ID: 18095883
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology May, 2008 | Pubmed ID: 18362364
Trial design for metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2008 | Pubmed ID: 18640946
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Investigational new drugs Apr, 2010 | Pubmed ID: 19262991
Patient selection for phase II trials.
American journal of clinical oncology Apr, 2009 | Pubmed ID: 19346816
Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis.
Chest Sep, 2009 | Pubmed ID: 19349386
The integration of chemotherapy and surgery for bladder cancer.
Journal of the National Comprehensive Cancer Network : JNCCN Jan, 2005 | Pubmed ID: 19813322
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Urologic oncology Nov-Dec, 2011 | Pubmed ID: 19959380
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology May, 2010 | Pubmed ID: 20159797
Bladder cancer: advances in treatment and research.
Clinical advances in hematology & oncology : H&O Apr, 2010 | Pubmed ID: 20505645
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
The Lancet. Oncology Sep, 2010 | Pubmed ID: 20537950
First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2010 | Pubmed ID: 20644092
Cabazitaxel.
Nature reviews. Drug discovery Sep, 2010 | Pubmed ID: 20811375
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Investigational new drugs Apr, 2012 | Pubmed ID: 20857170
Bladder cancer: current management and opportunities for a personalized approach.
The Mount Sinai journal of medicine, New York Nov-Dec, 2010 | Pubmed ID: 21105122
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan, 2011 | Pubmed ID: 21135284
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
The Lancet. Oncology Mar, 2011 | Pubmed ID: 21376284
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jun, 2011 | Pubmed ID: 21555688
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.
Clinical Medicine Insights. Oncology , 2011 | Pubmed ID: 21695098
Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Clinical genitourinary cancer Sep, 2011 | Pubmed ID: 21700509
Role of American Society of Clinical Oncology in low- and middle-income countries.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug, 2011 | Pubmed ID: 21709190
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
Urology Sep, 2011 | Pubmed ID: 21762967
Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
Clinical genitourinary cancer Mar, 2012 | Pubmed ID: 22130294
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Cancer Oct, 2012 | Pubmed ID: 22282219
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
Urologic oncology Oct, 2013 | Pubmed ID: 22300756
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Clinical genitourinary cancer Mar, 2012 | Pubmed ID: 22340631
Editorial comment.
The Journal of urology May, 2012 | Pubmed ID: 22425108
Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status.
American journal of clinical oncology Apr, 2012 | Pubmed ID: 22433994
Overcoming castration resistance in prostate cancer.
Current opinion in urology May, 2012 | Pubmed ID: 22472508
Novel molecular targets for the therapy of urothelial carcinoma.
Expert opinion on therapeutic targets May, 2012 | Pubmed ID: 22510032
The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.
Urologic oncology Nov, 2013 | Pubmed ID: 22513137
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
BJU international Dec, 2012 | Pubmed ID: 22520631
Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
CA: a cancer journal for clinicians Sep-Oct, 2012 | Pubmed ID: 22535487
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Urologic oncology Nov, 2013 | Pubmed ID: 22552048
The emerging role of circulating tumor cell detection in genitourinary cancer.
The Journal of urology Jul, 2012 | Pubmed ID: 22578722
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.
World journal of urology Oct, 2013 | Pubmed ID: 22622394
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
Cancer treatment reviews Nov, 2012 | Pubmed ID: 22651902
Trends in the use of cytoreductive nephrectomy in the United States.
Clinical genitourinary cancer Sep, 2012 | Pubmed ID: 22651971
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
The Journal of clinical investigation Jul, 2012 | Pubmed ID: 22653055
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
European urology Sep, 2012 | Pubmed ID: 22677572
Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?
The Journal of urology Aug, 2012 | Pubmed ID: 22704119
Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.
Cancer Dec, 2012 | Pubmed ID: 22707387
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
PloS one , 2012 | Pubmed ID: 22761653
Antiangiogenic treatment in metastatic urothelial cancer.
The Lancet. Oncology Aug, 2012 | Pubmed ID: 22819171
Editorial comment.
The Journal of urology Oct, 2012 | Pubmed ID: 22901587
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
European urology Jan, 2013 | Pubmed ID: 22917984
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
BJU international Dec, 2012 | Pubmed ID: 22985411
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Clinical genitourinary cancer Dec, 2012 | Pubmed ID: 23000202
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
The Lancet. Oncology Nov, 2012 | Pubmed ID: 23059047
Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
Journal of the National Cancer Institute Dec, 2012 | Pubmed ID: 23093559
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec, 2012 | Pubmed ID: 23150697
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
European urology Apr, 2013 | Pubmed ID: 23206856
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
World journal of urology Dec, 2013 | Pubmed ID: 23223962
Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer.
Clinical genitourinary cancer Dec, 2012 | Pubmed ID: 23228446
Emerging personalized approaches for the management of advanced urothelial carcinoma.
Expert review of anticancer therapy Dec, 2012 | Pubmed ID: 23253220
A prognostic model for metastatic renal-cell carcinoma.
The Lancet. Oncology Feb, 2013 | Pubmed ID: 23312462
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
Critical reviews in oncology/hematology Jul, 2013 | Pubmed ID: 23317774
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
Clinical genitourinary cancer Sep, 2013 | Pubmed ID: 23332638
Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Urologic oncology Jan, 2014 | Pubmed ID: 23428534
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Cancer treatment reviews Nov, 2013 | Pubmed ID: 23455076
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.
Cancer Jun, 2013 | Pubmed ID: 23456777
Metabolic and toxicological considerations of newly approved prostate cancer drugs.
Expert opinion on drug metabolism & toxicology Jul, 2013 | Pubmed ID: 23581700
Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches.
Clinical advances in hematology & oncology : H&O Feb, 2013 | Pubmed ID: 23598909
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
European urology Nov, 2013 | Pubmed ID: 23628492
The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
Clinical genitourinary cancer Sep, 2013 | Pubmed ID: 23673281
Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Cancer treatment reviews Feb, 2014 | Pubmed ID: 23684373
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
Urologic oncology Jan, 2014 | Pubmed ID: 23685020
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
European urology Feb, 2014 | Pubmed ID: 23706567
A new approach to second-line therapy for urothelial cancer?
The Lancet. Oncology Jul, 2013 | Pubmed ID: 23706984
Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Cancer Aug, 2013 | Pubmed ID: 23720197
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Cancer Aug, 2013 | Pubmed ID: 23720216
Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.
The Lancet. Oncology Jul, 2013 | Pubmed ID: 23742876
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Clinical genitourinary cancer Dec, 2013 | Pubmed ID: 23800847
Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Clinical genitourinary cancer Dec, 2013 | Pubmed ID: 23816526
Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Critical reviews in oncology/hematology Oct, 2013 | Pubmed ID: 23830806
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.
Targeted oncology Sep, 2014 | Pubmed ID: 23852656
Metastatic renal cancer: better never than late.
European urology Jun, 2014 | Pubmed ID: 23954087
Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Urologic oncology Jan, 2014 | Pubmed ID: 24055428
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
BJU international May, 2014 | Pubmed ID: 24219029
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Clinical genitourinary cancer Apr, 2014 | Pubmed ID: 24220220
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
BJU international Dec, 2014 | Pubmed ID: 24298897
Adverse event reporting in cancer clinical trial publications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan, 2014 | Pubmed ID: 24323037
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Urologic oncology May, 2014 | Pubmed ID: 24332646
Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
Clinical genitourinary cancer Apr, 2014 | Pubmed ID: 24355418
Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
European urology Aug, 2014 | Pubmed ID: 24433812
New developments in urothelial cancer.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting , 2012 | Pubmed ID: 24451754
Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.
Critical reviews in oncology/hematology Jun, 2014 | Pubmed ID: 24500033
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Cancer treatment reviews Jun, 2014 | Pubmed ID: 24629273
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?
European urology Nov, 2014 | Pubmed ID: 24631407
A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2014 | Pubmed ID: 24727324
T2 muscle-invasive bladder cancer.
Seminars in oncology Apr, 2014 | Pubmed ID: 24787300
Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
American journal of clinical oncology May, 2014 | Pubmed ID: 24824144
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
European urology Jan, 2015 | Pubmed ID: 24841777
Current approaches to the management of bladder cancer in older patients.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting , 2014 | Pubmed ID: 24857110
Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.
Cancer Oct, 2014 | Pubmed ID: 24965362
New drugs and treatment strategies in prostate cancer.
Clinical advances in hematology & oncology : H&O Jan, 2014 | Pubmed ID: 25000316
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology Sep, 2014 | Pubmed ID: 25023489
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
Clinical genitourinary cancer Dec, 2014 | Pubmed ID: 25035282
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
BJU international Jul, 2015 | Pubmed ID: 25046451
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
The oncologist Sep, 2014 | Pubmed ID: 25052451
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
Urologic oncology Feb, 2015 | Pubmed ID: 25065704
Rethinking cancer clinical trials for the future.
Future oncology (London, England) , 2014 | Pubmed ID: 25145425
Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Aug, 2014 | Pubmed ID: 25150635
Adult cancer clinical trials that fail to complete: an epidemic?
Journal of the National Cancer Institute Sep, 2014 | Pubmed ID: 25190726
Use of crowdsourcing for cancer clinical trial development.
Journal of the National Cancer Institute Oct, 2014 | Pubmed ID: 25217580
Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?
European urology Feb, 2015 | Pubmed ID: 25220371
Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Cancer Mar, 2014 | Pubmed ID: 25302607
Biomarkers for bladder cancer management: present and future.
American journal of clinical and experimental urology , 2014 | Pubmed ID: 25374904
Geographic accessibility to clinical trials for advanced cancer in the United States.
JAMA internal medicine Feb, 2015 | Pubmed ID: 25437434
Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2014 | Pubmed ID: 25453078
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Clinical genitourinary cancer Apr, 2015 | Pubmed ID: 25458370
How I treat bladder cancer in elderly patients.
Journal of geriatric oncology Jan, 2015 | Pubmed ID: 25482022
Survival of patients with stage IV lung cancer with diabetes treated with metformin.
American journal of respiratory and critical care medicine Feb, 2015 | Pubmed ID: 25522257
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
The Prostate May, 2015 | Pubmed ID: 25560638
Kidney cancer: Systemic therapy--differentiating the achievable from the achieved.
Nature reviews. Urology Mar, 2015 | Pubmed ID: 25600095
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.
The Journal of urology Jul, 2015 | Pubmed ID: 25623747
The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care.
The Journal of urology Jul, 2015 | Pubmed ID: 25623748
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
Cancer cell Feb, 2015 | Pubmed ID: 25670080
Clinical trial awareness: Changes over time and sociodemographic disparities.
Clinical trials (London, England) Jun, 2015 | Pubmed ID: 25673636
First-line treatment of metastatic disease: cisplatin-ineligible patients.
Hematology/oncology clinics of North America Apr, 2015 | Pubmed ID: 25836938
The landscape of precision cancer medicine clinical trials in the United States.
Cancer treatment reviews May, 2015 | Pubmed ID: 25864024
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Cancer Aug, 2015 | Pubmed ID: 25872978
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.
The Urologic clinics of North America May, 2015 | Pubmed ID: 25882560
Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.
Frontiers in oncology , 2015 | Pubmed ID: 26125012
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
Trials , 2015 | Pubmed ID: 26253548
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.
BMC medicine , 2015 | Pubmed ID: 26297150
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.
Urologic oncology Sep, 2015 | Pubmed ID: 26362343
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
Cancer chemotherapy and pharmacology Oct, 2015 | Pubmed ID: 26464352
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。